How will the proposed merger impact the generic drug market?

Question

Accepted Answer

The proposed merger of Pfizer's Upjohn unit and Mylan is poised to create a significant new entity in the lower-priced medicines sector, with potential implications for market dynamics.

The impending merger between Pfizer's off-patent drug division, Upjohn, and Mylan is set to establish a substantial new player in the global market for lower-priced medicines. This combination aims to revitalise sales growth for both companies, which have experienced a slowdown. The new entity, to be headquartered in the United States, will see Mylan shareholders holding just over 40% of the combined company, with Pfizer shareholders owning the rest.
Creation of a New Global Competitor

The union of Upjohn and Mylan is expected to result in a new global giant focused on lower-priced pharmaceuticals. This development occurs amidst considerable political pressure in the United States to reduce drug prices, particularly as blockbuster medications lose patent protection and face competition from generics. Mylan, for instance, has seen its top product, the EpiPen, encounter increased competition.
Addressing Slowing Sales Growth

Both Pfizer and Mylan are reportedly pursuing this merger as a strategy to re-energise their sales performance. The off-patent drug market, while significant, has faced challenges, including price erosion and increased competition. By combining forces, the new entity aims to leverage its scale and portfolio to achieve renewed growth in this segment.
Ownership Structure and Scale of Operations

Following the proposed transaction, Mylan shareholders are anticipated to hold slightly more than 40% of the newly formed company. The remaining equity will be held by Pfizer shareholders. Mylan's recent financial performance indicates a substantial operational base, with an annual turnover approaching US$12 billion last year and a market value just under US$10 billion. The leadership of the combined entity is expected to be drawn from the current head of Pfizer's Upjohn business.

Reading history

Hide →

This history is cleared when the page is closed.

How will the proposed merger impact the generic drug market?

Loading

Was this article helpful?

Helpful

Not helpful

Report an issue

1

0

0

Share with friends